生物
免疫系统
转录组
腺癌
肺癌
癌症研究
川地163
转移
人口
恶性肿瘤
免疫抑制
表型
小细胞肺癌
医学
癌症
免疫学
病理
癌
小细胞癌
基因表达
基因
遗传学
环境卫生
作者
Joseph M. Chan,Àlvaro Quintanal-Villalonga,Vianne R. Gao,Yubin Xie,Viola Allaj,Ojasvi Chaudhary,Ignas Masilionis,Jacklynn V. Egger,Andrew Chow,Thomas Walle,Marissa S. Mattar,Dig Vijay Kumar Yarlagadda,James L. Wang,Fathema Uddin,Michael Offin,Metamia Ciampricotti,Besnik Qeriqi,Amber Bahr,Elisa de Stanchina,Umesh Bhanot
出处
期刊:Cancer Cell
[Cell Press]
日期:2021-10-15
卷期号:39 (11): 1479-1496.e18
被引量:420
标识
DOI:10.1016/j.ccell.2021.09.008
摘要
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 SCLC transcriptomes. We observe greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a PLCG2-high SCLC phenotype with stem-like, pro-metastatic features that recurs across subtypes and predicts worse overall survival. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltrate and greater T cell dysfunction than SCLC-A. We identify a profibrotic, immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, PLCG2-high subpopulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI